View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

News

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔7/26/2017 9:30:49 AM 413

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent Allowed for Sygenus Secretions Technology for Acne

🕔7/10/2017 9:26:34 AM 990

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for a patent covering the composition, manufacture and use of the secretion stem cell technology platform, known as Sygenus, to treat acne. We recently informed the market of the new name for the secretions platform in our Q2 2017 Update.

Read Full Article

Regeneus Ltd (ASX:RGS) Q2 2017 Update

🕔7/5/2017 10:34:22 AM 927

Regeneus Ltd (ASX:RGS) provides the Company's latest newsletter for the quarter ended 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) to Receive Milestone Payment for Successful Phase I

🕔6/21/2017 9:10:44 AM 996

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it will receive a milestone payment of US$1m from AGC for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis. The company reported on the positive results of the trial on 22 May 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation to ChinaBio Partnering Forum

🕔5/31/2017 8:26:23 AM 1117

Regeneus Ltd (ASX:RGS) is pleased to provide the Company's latest presentation to ChinaBio Partnering Forum.

Read Full Article

Regeneus Ltd (ASX:RGS) Japanese Patent Office to Grant Key Patent for Progenza

🕔5/24/2017 9:20:35 AM 2166

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the Japanese Patent Office has issued a decision to grant a key patent covering the composition, manufacture and use of Progenza stem cell technology.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Clinical Trial Results for Progenza

🕔5/22/2017 9:52:04 AM 2359

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis, meeting the primary endpoint of safety and tolerability.

Read Full Article

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) CEO John Martin Talks about the Licensing of Progenza in Japan

🕔3/9/2017 9:00:20 AM 6930

With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.

Read Full Article

Regeneus Ltd (ASX:RGS) Enters Into Collaborative Agreement With Asahi Glass (TYO:5201) To Commercialize Progenza

🕔1/13/2017 2:19:42 PM 6466

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced that it has entered into a strategic collaboration and licensing agreement with AGC Asahi Glass (AGC) (TYO:5201), a world-leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals.

Read Full Article

Regeneus Ltd (ASX:RGS) FY16 Results Presentation

🕔8/24/2016 9:59:03 AM 2394

Regeneus Ltd (ASX:RGS) are pleased to provide a Company Presentation for the Full Year Results for FY16.

Read Full Article
###

41,017 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 716) (Last 30 Days: 2374) (Since Published: 20630) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Company Reports

Presentations

Research Report

Quarterly Report

Social Media